Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Watanabe

Showing results (771-780 of 817) with videos related to

Pageof 82
Sort By:
Cancer Research and Treatment|November 1, 2024
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective StudyNaoya Nishioka, Tae Hata, Tadaaki Yamada, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2024
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047)Tetsuhiko Asao, Takehito Shukuya, Kohei Uemura, et al.
Cancer Science|January 18, 2026
Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive CancersYuya Murase, Shigeki Nanjo, Sachiko Arai, et al.
Scientific Reports|May 6, 2026
Muscle loss and pentraxin-3 as predictors of immunotherapy outcomes in non-small cell lung cancer: a prospective studyTakaaki Masuda, Satoshi Watanabe, Ryo Suzuki, et al.
American Journal of Medical Genetics. Part A|January 20, 2016
Detailed analysis of 26 cases of 1q partial duplication/triplication syndromeSatoshi Watanabe, Kenji Shimizu, Hirofumi Ohashi, et al.
Scientific Reports|May 16, 2019
Analysis of systemic lupus erythematosus-related interstitial pneumonia: a retrospective multicentre studyNoriyuki Enomoto, Ryoko Egashira, Kazuhiro Tabata, et al.
Nature Communications|January 18, 2019
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cellsHirokazu Taniguchi, Tadaaki Yamada, Rong Wang, et al.
Translational Lung Cancer Research|May 19, 2025
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in JapanShiho Goda, Tadaaki Yamada, Kenji Morimoto, et al.
The Oncologist|November 28, 2019
Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 StudyKazunari Tateishi, Ryo Ko, Takehito Shukuya, et al.
Translational Lung Cancer Research|September 29, 2021
Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated <i>EGFR</i>-mutated advanced non-small cell lung cancer: a prospective observational studyAkihiro Yoshimura, Tadaaki Yamada, Yusuke Okuma, et al.
Pageof 82

Showing results (771-780 of 817) with videos related to

Sort By:
Pageof 82
Cancer Research and Treatment|November 1, 2024
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective StudyNaoya Nishioka, Tae Hata, Tadaaki Yamada, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2024
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047)Tetsuhiko Asao, Takehito Shukuya, Kohei Uemura, et al.
Cancer Science|January 18, 2026
Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive CancersYuya Murase, Shigeki Nanjo, Sachiko Arai, et al.
Scientific Reports|May 6, 2026
Muscle loss and pentraxin-3 as predictors of immunotherapy outcomes in non-small cell lung cancer: a prospective studyTakaaki Masuda, Satoshi Watanabe, Ryo Suzuki, et al.
American Journal of Medical Genetics. Part A|January 20, 2016
Detailed analysis of 26 cases of 1q partial duplication/triplication syndromeSatoshi Watanabe, Kenji Shimizu, Hirofumi Ohashi, et al.
Scientific Reports|May 16, 2019
Analysis of systemic lupus erythematosus-related interstitial pneumonia: a retrospective multicentre studyNoriyuki Enomoto, Ryoko Egashira, Kazuhiro Tabata, et al.
Nature Communications|January 18, 2019
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cellsHirokazu Taniguchi, Tadaaki Yamada, Rong Wang, et al.
Translational Lung Cancer Research|May 19, 2025
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in JapanShiho Goda, Tadaaki Yamada, Kenji Morimoto, et al.
The Oncologist|November 28, 2019
Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 StudyKazunari Tateishi, Ryo Ko, Takehito Shukuya, et al.
Translational Lung Cancer Research|September 29, 2021
Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated <i>EGFR</i>-mutated advanced non-small cell lung cancer: a prospective observational studyAkihiro Yoshimura, Tadaaki Yamada, Yusuke Okuma, et al.
Pageof 82